News & Updates

Show Multimedia Only
Advanced liver fibrosis a red flag for poor outcomes in T2D

Advanced liver fibrosis a red flag for poor outcomes in T2D

18 Jul 2023

Among individuals with type 2 diabetes (T2D), the risk of poor outcomes such as heart failure and hospitalizations is high in the presence of advanced liver fibrosis, according to a study.

18 Jul 2023
Danuglipron helps with glucose control, weight loss in T2D

Danuglipron helps with glucose control, weight loss in T2D

15 Jul 2023 byJairia Dela Cruz

The glucagon-like peptide 1 receptor (GLP-1R) agonist danuglipron appears to be beneficial in the treatment of patients with type 2 diabetes (T2D), yielding reductions in glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), and body weight, without fasting restrictions, as shown in the results of a phase IIb study.

15 Jul 2023